目錄:北京北納創(chuàng)聯(lián)生物技術(shù)研究院>>ATCC>>ATCC細(xì)胞>> ATCC CRL-3226 VMM5A人黑色素瘤細(xì)胞-ATCC細(xì)胞庫(kù)代理
| 參考價(jià) | 面議 |
| 參考價(jià) | 面議 |
更新時(shí)間：2024-11-09 16:31:44瀏覽次數(shù)：3958評(píng)價(jià)
聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息，謝謝!
北京北納創(chuàng)聯(lián)生物技術(shù)研究院是一家專業(yè)從事標(biāo)準(zhǔn)物質(zhì)、計(jì)量分析儀器和精細(xì)化工產(chǎn)品研發(fā)及銷售的科研單位。是國(guó)內(nèi)標(biāo)準(zhǔn)物質(zhì)提供商之一，代理銷售國(guó)內(nèi)外數(shù)萬(wàn)種標(biāo)準(zhǔn)物質(zhì)、微生物、菌種、細(xì)胞類等產(chǎn)品。
北京標(biāo)準(zhǔn)物質(zhì)網(wǎng)隸屬于北京北納創(chuàng)聯(lián)生物技術(shù)研究院，具備強(qiáng)大的分析測(cè)試、技術(shù)開(kāi)發(fā)、*、物流管理和售后服務(wù)能力，并與國(guó)內(nèi)外眾多檢測(cè)機(jī)構(gòu)、科研院校和工廠企業(yè)有著良好和穩(wěn)定的合作關(guān)系，具有較強(qiáng)的權(quán)威性和影響力。
北納生物也隸屬于北京北納創(chuàng)聯(lián)生物技術(shù)研究院，實(shí)驗(yàn)基地總占地面積16畝，并設(shè)有細(xì)胞庫(kù)、微生物菌種保藏庫(kù)，細(xì)胞培養(yǎng)、菌種培養(yǎng)等實(shí)驗(yàn)室。擁有細(xì)胞和菌株2萬(wàn)余株，并設(shè)有生物資源信息庫(kù)，收錄信息達(dá)20余萬(wàn)株。致力于提供實(shí)驗(yàn)室綜合解決方案，為廣大客戶服務(wù)。
經(jīng)營(yíng)范圍：
國(guó)家標(biāo)準(zhǔn)物質(zhì)、國(guó)內(nèi)外標(biāo)準(zhǔn)品、對(duì)照品、實(shí)驗(yàn)耗材、試劑、菌株、細(xì)胞、ATCC、培養(yǎng)基、血清、冶金標(biāo)樣、標(biāo)準(zhǔn)氣體、試劑盒等，歡迎查詢！
人黑色素瘤細(xì)胞-ATCC細(xì)胞庫(kù)代理
ATCC CRL-3226 VMM5A
| 基本信息 | |
| 資源編號(hào) | ATCC CRL-3226 |
| 資源名稱 | VMM5A |
| 種屬 | 人黑色素瘤細(xì)胞 |
| 類型 | Melanocyte |
| 形態(tài) | Epithelial-like |
| 提供形式 | 凍存管 |
| 致病類型 | Melanoma, Stage IIIC; malignant |
| 安全等級(jí) | 1 |
| 模式菌株 | 未知 |
| 應(yīng)用領(lǐng)域 | Drug screening Development of targeted therapy Development of combination therapy Tumor vaccine development |
| 說(shuō)明書(shū) | 點(diǎn)擊下載 |
| 產(chǎn)品圖片 | 點(diǎn)擊下載 |
| 培養(yǎng)方法 | |
| 培養(yǎng)基 | 90%RPMI-1640+10%FBS |
| 傳代方法 | Volumes are for a T-75 flask; Adjust accordingly Remove and discard the cell culture medium from the flask. Rinse the cell monolayer with Dulbecco’s PBS without calcium or magnesium and remove. Add 3 to 4 ml of the trypsin-EDTA solution, rotate flask to rinse cell monolayer, remove trypsin solution, and incubate at 37oC. Once the cells appear to be detached, add 10 ml of complete growth medium with a pipette to the cell suspension to inactivate the trypsin. Gently wash any remaining cells from the growth surface of the flask. Check the cells with the microscope to be sure that most (>95%) are single cells. If cell clusters are apparent, continue to disperse the cells with gentle pipetting. Subculture as necessary. Place the flask back into the incubator. Examine the culture the following day to ensure the cells have reattached and are actively growing. Repeat when cells reach confluence. |
| 生長(zhǎng)條件 | 95%空氣+5%二氧化碳37攝氏度 |
| 生長(zhǎng)特性 | 貼壁生長(zhǎng) |
| 存儲(chǔ)條件 | 50% RPMI-1640+40%FBS+10%DMSO液氮 |
| 詳細(xì)說(shuō)明 | |
| Age | 81 |
| Gender | Male |
| Ethnicity | Caucasian |
| Derivation | Derived from tumors taken from tumor-involved lymph nodes from patients at the University of Virginia |
| Clinical Data | Primary Site Right Posterior Shoulder; Metastatic Site Lymph Node, Right Neck |
| Antigen Expression | Positives High VEGF-R2, Low GP100, Tyrosinase, Low MAGE-A1, MMP-1 |
| HLA Typing | A2.1,A1101,B39,B44, BW4,BW6,C7(17)DR7, DR8,DR11,DQ2,DQ7 |
| STR Profile | Amelogenin X,Y D5S818 9 D7S820 9,10 D13S317 12 D16S539 12 vWA 16 TH01 9.3 TPOX 8,11 CSF1PO 11 |
| Sterility Tests | Pass |
| Passage History | Unknown. 2 passages from 2003 frozen cell line stock, but it is not known how long the line was in culture after being established from tumor tissue obtained in 1992. |
| Year of Origin | 1992 |
| 描述 | NRAS: wt CDKN2A: wt BRAF Mutation: V600E APC Mutation PDGFRA Mutation: D842V PTEN Mutation: R173H more sensitive to BAY43-9006 (BRAF kinase inhibitor) and to rapamycin (mTOR kinase inhibitor), compared to cell lines with wild-type B-Raf |
人黑色素瘤細(xì)胞-ATCC細(xì)胞庫(kù)代理
溫馨提示：
本店商品種類眾多，因鋪位有限商品未全部上架，如果沒(méi)有找到您想要的商品可以咨詢客服，我們會(huì)耐心解答，祝您購(gòu)物愉快！
(空格分隔,最多3個(gè),單個(gè)標(biāo)簽最多10個(gè)字符)
會(huì)員.png)
8
化工儀器網(wǎng)